MED12 is altered in 5.02% of melanoma patients [3].

MED12 is an inclusion criterion in 1 clinical trial for melanoma, of which 0 are open and 1 is closed. Of the trial that contains MED12 status and melanoma as inclusion criteria, 1 is phase 1 (0 open) [4].

MED12 is altered in 4.56% of colorectal carcinoma patients [3].

MED12 is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MED12 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

MED12 is altered in 4.93% of non-small cell lung carcinoma patients [3].

MED12 is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MED12 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

MED12 is altered in 4.36% of bladder carcinoma patients [3].

MED12 is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MED12 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

MED12 is altered in 3.62% of glioblastoma patients [3].

MED12 is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains MED12 status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [4].

MED12 is altered in 3.77% of malignant solid tumor patients [3].

MED12 is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains MED12 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [4].

MED12 is altered in 3.05% of head and neck carcinoma patients [3].

MED12 is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MED12 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

MED12 is altered in 3.08% of lymphoma patients [3].

MED12 is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MED12 status and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

MED12 is altered in 3.07% of sarcoma patients [3].

MED12 is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains MED12 status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

MED12 is altered in 3.61% of ovarian carcinoma patients [3].

MED12 is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MED12 status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

MED12 is altered in 2.46% of breast carcinoma patients [3].

MED12 is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MED12 status and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

MED12 is altered in 1.67% of pancreatic carcinoma patients [3].

MED12 is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 0 are open and 1 is closed. Of the trial that contains MED12 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

MED12 is altered in 1.01% of anaplastic astrocytoma patients [3].

MED12 is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains MED12 status and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [4].